NCT04436497View on ClinicalTrials.gov

HEALEY ALS Platform Trial - Regimen A Zilucoplan

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

April 13, 2022

Study Completion Date

May 4, 2022

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Zilucoplan

"Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily"

DRUG

Matching Placebo

"Drug: Matching Placebo~Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection"

Trial Locations (1)

02114

Healey Center for ALS at Mass General, Boston

Sponsors

Collaborators (1)

Ra Pharmaceuticals
All Listed Sponsors
collaborator

Ra Pharmaceuticals

INDUSTRY

lead

Merit E. Cudkowicz, MD

OTHER